The deal would be the largest biopharma acquisition this year, and a sign that Merck is willing to spend more than usual to diversify its business beyond the cancer drug Keytruda. The company also completed a strategic divesture this year to improve its focus on key growth areas. Merck completed Organon & Co. Spinoff in Jun-21, and believes the transaction will deliver significant benefits for both companies.
The deal also adds FDA-approved blood-related disorder drug Reblozyl, which Acceleron markets with partner Bristol Myers Squibb (BMY.N), to Merck’s portfolio.
• Executive Summary
• Deal Overview
• Company Overview – Acceleron Pharma Inc
• Company Overview – Merck & Co., Inc.
No of Pages : 65